Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Price Target Raised to $3.00

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) had its target price boosted by equities research analysts at D. Boral Capital from $2.00 to $3.00 in a research report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. D. Boral Capital’s price objective indicates a potential upside of 60.86% from the stock’s current price.

Separately, HC Wainwright reissued a “buy” rating on shares of Lineage Cell Therapeutics in a report on Friday. Three analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $5.00.

Lineage Cell Therapeutics Stock Up 1.4%

Shares of NYSEAMERICAN LCTX traded up $0.03 during trading on Friday, reaching $1.87. 1,244,653 shares of the company traded hands, compared to its average volume of 1,121,219. Lineage Cell Therapeutics has a 52-week low of $0.37 and a 52-week high of $2.09. The stock has a market capitalization of $429.57 million, a PE ratio of -6.43 and a beta of 1.74. The firm has a 50 day simple moving average of $1.72 and a 200-day simple moving average of $1.64.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last issued its quarterly earnings results on Thursday, March 5th. The company reported $0.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.07. The company had revenue of $6.61 million during the quarter, compared to the consensus estimate of $1.96 million. Lineage Cell Therapeutics had a negative return on equity of 72.02% and a negative net margin of 625.53%. As a group, research analysts predict that Lineage Cell Therapeutics will post -0.12 EPS for the current year.

Institutional Trading of Lineage Cell Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Citizens Financial Group Inc. RI acquired a new position in shares of Lineage Cell Therapeutics in the third quarter worth about $25,000. SG Americas Securities LLC acquired a new position in Lineage Cell Therapeutics in the 4th quarter worth about $25,000. Jump Financial LLC purchased a new position in Lineage Cell Therapeutics during the second quarter worth approximately $28,000. Define Financial LLC purchased a new position in Lineage Cell Therapeutics during the fourth quarter worth approximately $33,000. Finally, DLD Asset Management LP acquired a new stake in Lineage Cell Therapeutics in the fourth quarter valued at approximately $33,000. Institutional investors and hedge funds own 62.47% of the company’s stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.